NanoViricides Inc. (NNVC.OB) Major Shareholder Completes Programmed Share Sale; Appropriates Proceeds
NanoViricides Inc. is a development stage company focused on creating nanomaterials for viral therapy, including drug candidates for H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, and other viral diseases. The company today announced that TheraCour Pharma Inc., NanoViricide’s major shareholder, completed its programmed sale of shares of NanoViricide in December 2009. In the press release, the company said the programmed sale under Securities and Exchange Commission Rule 10b5-1 was authorized and initiated in February, 2009. TheraCour plans on using the proceeds to improve its laboratories, which will allow for larger production space for upcoming…